- In July 2024, BioNet Europe, the French branch of BioNet, announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV). This standalone vaccine is designed for individuals who need a pertussis-only booster shot and are current with their diphtheria and tetanus vaccinations.
- In October 2023, Adimmune Corporation announced the successful extension of the marketing authorization for its tetanus vaccine. The company is set to begin the steady supply of at least one million doses annually for the domestic market in Taiwan starting as early as November 2023. This tetanus vaccine helps prevent infections caused by Clostridium tetani bacteria, which can lead to neurological conditions such as muscle stiffness and convulsions.
- In April 2022, the Research Foundation for Microbial Diseases of Osaka University and Mitsubishi Tanabe Pharma Corporation announced that BIKEN had submitted an application for marketing authorization to the Ministry of Health, Labour and Welfare for their combination vaccine (BIKEN Clinical Trial Code: BK1310, MTPC Clinical Trial Code: MT-2355). This vaccine, developed jointly by the two organizations, is intended for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis (polio), and Haemophilus influenzae type b (Hib).
- In February 2021, Dynavax Technologies Corporation and Serum Institute of India (SIIPL) jointly announced that the first participant had been dosed in a Phase 1 clinical trial for a tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate adjuvanted with CpG 1018. The two companies are collaborating to develop this adjuvanted Tdap vaccine to overcome the limitations of currently available acellular pertussis vaccines.
- In June 2021, VAXELIS, a hexavalent (six-in-one) combination vaccine developed through a U.S.-based partnership between Merck and Sanofi Pasteur, the global vaccines division of Sanofi, became available in the U.S. VAXELIS is the first and only vaccine in the U.S. to combine Diphtheria and Tetanus Toxoids, Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate, and Hepatitis B.
Frequently Asked Questions
Companies such as GSK plc. (U.K.), Dynavax Technologies Corporation (U.S.), AJ Vaccines A/S (Denmark), Astellas Pharma Inc. (Japan) and BioNet-Asia (Thailand), are the major companies in the diphtheria, tetanus and pertussis vaccine market.
In July 2024, BioNet Europe, the French branch of BioNet, announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV). In October 2023, Adimmune Corporation announced the successful extension of the marketing authorization for its tetanus vaccine.
The countries covered in the diphtheria, tetanus and pertussis vaccine market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
